Clinical Trial Update: High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose erythropoietin in extremely premature infants to prevent or attenuate brain injury has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Injury
• Intraventricular Hemorrhage
• Periventricular Leukomalacia

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Atlantic Health System | Conditions: Infant, Premature, Erythropoietin | Phase 2 | Status: TERMINATED